 Newstalk ZB | Indian patent appeal board upholds compulsory license on Bayer's Nexavar The Pharma Letter ... grant of a compulsory licence has now been issued by India's Intellectual Property Appellate Board (IPAB) in Chennai, upholding the March 2012 granting of the first compulsory license for the firm's kidney and liver cancer drug Nexavar (sorafenib ... India rejects German transnational's cancer drug patent appeal Landmark ruling against patent drugs in India India Rejects Bayer Plea Against Cheap Cancer Drug |
